Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified?
The Breast Journal Oct 16, 2017
Sorrentino L, et al. - Researchers sought to determine preoperative features predictive of nodal involvement in patients with ductal carcinoma in situ (DCIS) of the breast. Exclusion from sentinel node biopsy may not always be sufficiently justified by a preoperative diagnosis of DCIS, including advanced biopsy systems such as vacuum-assisted breast biopsy. In addition, axillary evaluation was recommended to be considered in DCIS patients with associated Breast Imaging Reporting and Data System (BI-RADS) >4, lesion extension ≥20 mm, comedo type, and above all multifocal disease.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries